Highest-materiality recent filing
Akari Therapeutics raises ~$5.5M via private placement of ADSs and warrants
Gross proceeds of ~$5.5M from 1,470,588 ADSs at $3.74 per unit; three closings through July 15, 2026.
Akari Therapeutics announces 1-for-40 reverse ADS ratio change to meet Nasdaq bid price requirement
ADS ratio changes from 1:2,000 to 1:80,000 ordinary shares; each 40 current ADSs become 1 new ADS effective March 31, 2026.
Akari shareholders approve warrant exercises and share issuances at special meeting
Shareholders voted overwhelmingly to approve exercisability of Series G, Placement Agent, Pre-Funded, and Note Exchange warrants.
Akari raises ~$5M in equity; exchanges $4M notes for warrants
Gross proceeds ~$5M from 10,043,774 ADSs at $0.3883/unit plus pre-funded warrants to insiders for $1M+.
Akari shareholders approve share sub-division, warrant exercise, and new articles
Approved exercisability of warrants issued in October 2025 offering under Nasdaq Listing Rule 5635(d).
Akari Therapeutics furnishes investor presentation for conferences
Investor presentation furnished as Exhibit 99.1 on December 8, 2025.
Akari Therapeutics receives Nasdaq deficiency notice for bid price below $1.00
Nasdaq notified Akari on Nov 24, 2025 that ADS closing bid price below $1.00 for 30 consecutive business days.
Akari Therapeutics appoints Kameel Farag as interim CFO
Kameel Farag appointed interim CFO effective October 22, 2025; succeeds Torsten Hombeck.
Akari prices $2.5M registered direct offering of ADSs and warrants at $0.80/unit
Issued 3,125,000 ADSs (each representing 2,000 ordinary shares) and Series E/F warrants to purchase up to 3,125,000 ADSs each, all at $0.80 per unit.
Akari Therapeutics raises $2.5M in registered direct offering and warrant issuance
Gross proceeds of $2.5M from sale of 3,125,000 ADSs at $0.80 per ADS; Ladenburg Thalmann as placement agent.
Akari closes final tranche of August 2025 notes offering for $250K purchase price
Aggregate purchase price of $3 million for notes with 20% original issuance discount.
Akari Therapeutics extends April 2023 notes to Aug 2026, closes $500k tranche, reveals PH1 ADC data
April 2023 notes maturity extended to Aug 31, 2026; conversion/exercise price amended to $0.81/ADS ($0.000405 per ordinary share).
Akari Therapeutics enters $25M ELOC with White Lion Capital; CFO resigns
Entered $25M equity line with White Lion Capital; commitment period through Aug 29, 2028.
Akari raises $2.26M via unsecured notes with 20% OID; Chairman Huh exchanges prior loan
Issued notes with aggregate purchase price of $2,261,000 and principal amount of $2,826,250; maturity 12 months from closing.
Akari Therapeutics posts updated investor presentation; details not disclosed
Company furnished an updated corporate presentation as Exhibit 99.1 on Form 8-K.
Shareholders approved increase in 2023 Plan share pool by 11,026,000,000 ordinary shares (5,513,000 ADSs) to 19,806,000,000 ordinary shares.
Akari Therapeutics Q1 net loss $3.7M, cash $2.6M; advances ADC pipeline
Net loss from operations $3.7M in Q1 2025 vs $5.6M in Q1 2024; R&D spend down to $0.8M.
Akari Therapeutics FY2024 net loss $21.6M; cash runway into Sep 2025; new CEO named
FY2024 net loss from operations $21.6M vs $16.8M in 2023; R&D $7.0M, G&A $9.7M.
Abizer Gaslightwala appointed President and CEO effective ~April 21, 2025; prior SVP at Jazz Pharmaceuticals.
Akari Therapeutics raises ~$7.1M via ADS/warrant offering with board participation
Gross proceeds ~$7.1M from sale of 6,637,626 ADS units (or prefunded warrants) plus Series A/B warrants; includes $1M note termination by Chairman.
Akari Therapeutics updates corporate presentation on bi-functional ADC pipeline
Updated slide deck highlights next-generation precision bi-functional antibody drug conjugate platform.
Akari Therapeutics appoints Samir R. Patel as permanent CEO, adds Abizer Gaslightwala to board
Dr. Samir R. Patel appointed CEO effective Dec 16, 2024; he served as interim CEO since May 2024.
Akari Therapeutics appoints Torsten Hombeck as CFO effective Dec 16, 2024
Torsten Hombeck appointed CFO effective Dec 16, 2024; previously served as CFO from Oct 2019 to June 2024.
Akari Therapeutics: Interim CFO Wendy DiCicco departs; CEO Samir Patel assumes interim PFO/PAO roles
Wendy DiCicco's consulting agreement terminated on December 6, 2024, ending her role as Interim CFO, PFO, and PAO.
Akari Therapeutics completes merger with Peak Bio, secures $3.2M PIPE and $50M ELOC term sheet
Merger closed; Peak Bio shareholders received 0.2935 Akari ADS per share, representing ~48.4% of combined entity on fully diluted basis.
Akari shareholders approve Peak Bio merger; close targeted Nov 13, Nasdaq listing risk seen removed
All six merger proposals passed with ~99% of vote; 14.6B shares for Merger Allotment.
Akari Therapeutics receives Nasdaq delisting notice; plans to appeal
Received Nasdaq delisting determination on Oct 1, 2024 for non-compliance with $2.5M stockholders' equity requirement.
Akari updates Peak Bio merger conditions, CEO compensation revised, pipeline prioritization
Merger with Peak Bio conditions include Peak Bio net cash > -$13.5M and PIPE net proceeds ≥ $10M; expected closing Q4 2024.
No material event disclosed; 8-K contains only XBRL context references
Filing reports Items 8.01 and 9.01 but provides no narrative or financial data.
Akari Therapeutics discloses CEO separation terms: $450K payment, RSU vesting/forfeiture
Rachelle Jacques stepped down as President and CEO effective May 1, 2024.
Akari appoints Samir Patel as interim CEO; merger with Peak Bio on track for Q4 2024
Samir R. Patel appointed interim CEO with employment contract consisting solely of equity compensation.
Akari Therapeutics shareholders approve all proposals at adjourned 2024 AGM
Initial June 27 meeting lacked quorum; adjourned to June 28.
Samir R. Patel appointed Interim President & CEO effective May 1; agreement signed May 31.
Akari closes ~$7.6M private placement of ADSs and warrants
Sold 3,817,553 ADSs and warrants at $1.885/unit to investors including chairman and interim CEO; 212,201 units to close later.
Akari Therapeutics Q1 net loss $5.6M; cash $1.3M; merges with Peak Bio, cuts 67% workforce
Q1 net loss $5.6M vs net income $1.0M in Q1 2023; adjusted net loss $6.2M excluding warrant gains.
Akari Therapeutics reduces workforce by 67% after suspending HSCT-TMA program
Workforce reduction of ~67% implemented May 1, 2024; includes elimination of senior management positions.
Akari Therapeutics CEO and COO exit; merger portfolio prioritizes ADC and GA over other programs
Rachelle Jacques stepped down as CEO effective May 1; COO Melissa Bradford-Klug terminated without cause same date.
Akari Therapeutics receives Nasdaq delisting notice for stockholders' equity deficit
Stockholders' deficit of $229,000 at Dec 31, 2023 violates Nasdaq's $2.5M minimum equity requirement.
Akari Therapeutics FY2023 net loss narrows to $10M; all-stock merger with Peak Bio
FY2023 net loss $10.0M vs $17.7M in 2022; cash $3.8M at year-end, raised $2.0M in March 2024.
Akari Therapeutics raises ~$1.615M in private placement of ADSs for working capital
Pricing at lower of $1.57 or 0.7× 15-day VWAP, floor $1.12 per ADS, each ADS representing 2,000 ordinary shares.
As previously disclosed, effective as of the Effective Time and pursuant to the terms of the Merger Agreement, the Akari Board appointed Hoyoung Huh, M.D., Ph. D, James Neal and Sandip Patel, each of whom were members of the board of directors of Peak Bio, to serve as directors for a term commencing upon the Effective Time.
Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.
Dr. Huh will serve as the non-executive chairman of the Akari Board as of the Effective Time.
Wa’el Hashad and Donald Williams resigned as directors of Akari and any committees thereof.
As previously disclosed, effective as of the Effective Time and pursuant to the terms of the Merger Agreement, the Akari Board appointed Hoyoung Huh, M.D., Ph. D, James Neal and Sandip Patel, each of whom were members of the board of directors of Peak Bio, to serve as directors for a term commencing upon the Effective Time.
the appointment of Robert Bazemore to serve as a director of the Board, effective as of September 17, 2024
Rachelle Jacques stepped down as the President and Chief Executive Officer of the Company, effective May 1, 2024
As previously disclosed, on April 25, 2024, the board of directors (the “Board”) of Akari Therapeutics, Plc (the “Company”) appointed Samir R. Patel, M.D., a member of the Board, as Interim President and Chief Executive Officer, effective May 1, 2024, to serve in such capacities until such time as determined by the Board.
On May 7, 2024, Rachelle Jacques resigned from the Board of Directors (the “Board”), effective May 7, 2024.
our Chief Operating Officer, Melissa Bradford-Klug, was terminated without cause, effective May 1, 2024.
Rachelle Jacques stepped down as the President and Chief Executive Officer of Akari Therapeutics, Plc (the “Company”), effective May 1, 2024.
the Board appointed Samir R. Patel, M.D., a member of the Board, to Interim President and Chief Executive Officer, effective May 1, 2024
Max materiality 0.85 · Median 0.60 · Most common event other_material